

NOVA SCOTIA PROVINCIAL PHARMACARE PROGRAMS

Request for Coverage of Hepatitis C Treatments

Please refer to the Nova Scotia Formulary for the full criteria: <https://novascotia.ca/dhw/pharmacare/documents/formulary.pdf>

PATIENT INFORMATION			
PATIENT SURNAME	PATIENT GIVEN NAME	HEALTH CARD NUMBER	DATE OF BIRTH
PATIENT ADDRESS			
DIAGNOSTIC INFORMATION			
Lab-confirmed Hepatitis C, Genotype(s): <input type="checkbox"/> 1a <input type="checkbox"/> 1b <input type="checkbox"/> 2 <input type="checkbox"/> 3 <input type="checkbox"/> 4 <input type="checkbox"/> 5 <input type="checkbox"/> 6			
Evidence of HCV viremia (e.g., HCV viral load) within 6 months of this request? <input type="checkbox"/> Yes <input type="checkbox"/> No			
Please indicate ALL that apply:			
1. CIRRHOsis STATUS: <input type="checkbox"/> None <input type="checkbox"/> Compensated <input type="checkbox"/> De-compensated			
2. TRANSPLANT: <input type="checkbox"/> Post liver transplant			
3. CO-INFECTION: <input type="checkbox"/> HCV/HIV			
DRUG(S) AND DURATION OF THERAPY			
Drug	Duration (weeks)	Drug	Duration (weeks)
Sofosbuvir/Velpatasvir (<i>Epclusa</i>)	<input type="checkbox"/> 12	Sofosbuvir (<i>Sovaldi</i>)	<input type="checkbox"/> 12 <input type="checkbox"/> 24
Sofosbuvir/Ledipasvir (<i>Harvoni</i>)*	<input type="checkbox"/> 8* <input type="checkbox"/> 12* <input type="checkbox"/> 24	Sofosbuvir/Velpatasvir/ Voxilaprevir (<i>Vosevi</i>)	<input type="checkbox"/> 12
Elbasvir/Grazoprevir (<i>Zepatier</i>)	<input type="checkbox"/> 8 <input type="checkbox"/> 12 <input type="checkbox"/> 16	Glecaprevir/Pibrentasvir (<i>Maviret</i>)	<input type="checkbox"/> 8 <input type="checkbox"/> 12 <input type="checkbox"/> 16
Regimen			
In combination with ribavirin [†] ?			
<input type="checkbox"/> Yes <input type="checkbox"/> No			
*Genotype 1, treatment-naïve patients without cirrhosis, who have a pre-treatment HCV RNA level less than 6 million IU/mL and are mono-HCV infected only are eligible for 8 weeks of coverage. Genotype 1, treatment-naïve patients without cirrhosis, who have a pre-treatment HCV RNA level greater than or equal to 6 million IU/mL are eligible for 12 weeks of coverage. Please refer to Formulary for complete criteria. [†] Requests for ribavirin will be considered on a case by case basis and will require a completed form for adjudication.			
PREVIOUS HEPATITIS C THERAPIES			
<input type="checkbox"/> Treatment-Naïve			
<input type="checkbox"/> Treatment-Experienced (please provide details below)			
Treatment(s)/Date(s)		Response to treatment(s)	
		<input type="checkbox"/> Intolerance	<input type="checkbox"/> Null responder
		<input type="checkbox"/> Relapse	<input type="checkbox"/> On-treatment virologic failure
			<input type="checkbox"/> Partial responder
			<input type="checkbox"/> Other _____
		<input type="checkbox"/> Intolerance	<input type="checkbox"/> Null responder
		<input type="checkbox"/> Relapse	<input type="checkbox"/> On-treatment virologic failure
			<input type="checkbox"/> Partial responder
			<input type="checkbox"/> Other _____
PRESCRIBER NAME & ADDRESS			
_____ LICENCE #		_____ PRESCRIBER SIGNATURE	
		_____ DATE	

If you need assistance, please contact the Pharmacare Office at (902) 496-7001 or 1-800-305-5026

Please return form to: Nova Scotia Pharmacare Programs
P.O. Box 500, Halifax, NS B3J 2S1
Fax: (902) 496-4440

